GRTX — Galera Therapeutics, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1563577 ·
Last close
$0.10
Market Cap
$19.33M
52W High
$0.15
52W Low
$0.04
ADV30
578,129
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,655,000 | -1,606,000 | 6,164,000 | 5,500,000 | 1,141,000 |
| Dec 2025 | 0 | — | -1,508,000 | 153,104,000 | 7,196,000 | 6,375,000 | 645,000 |
| Sep 2025 | 0 | — | -1,436,000 | -1,388,000 | 5,002,000 | 4,473,000 | 154,224,000 |
| Jun 2025 | 0 | — | -1,135,000 | -1,075,000 | 6,048,000 | 5,230,000 | 153,993,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,049,000
Investing CF
$3,454,000
Financing CF
$635,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.12
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-307,314,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-6,042,000
Pretax Income TTM
$149,049,000
Interest Exp TTM
$0
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -6,042,000 | 149,049,000 | 7,196,000 | 645,000 | — | -6,049,000 |
| Dec 2024 | 0 | -14,153,000 | -18,957,000 | 10,101,000 | 153,770,000 | — | -12,145,000 |
| Dec 2023 | 0 | -46,951,000 | -59,082,000 | 26,141,000 | 157,326,000 | — | -44,848,000 |
| Dec 2022 | 0 | -51,226,000 | -62,222,000 | 44,036,000 | 153,217,000 | — | -43,426,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTXR | Citius Pharmaceuticals, Inc. | $19.13M | $0.70 | — |
| LPCN | Lipocine Inc. | $18.63M | $2.26 | — |
| AEON | AEON Biopharma, Inc. | $20.26M | $0.77 | — |
| AKTX | Akari Therapeutics Plc | $20.39M | $17.81 | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $17.86M | $1.42 | — |
News headlines (Yahoo Finance, 1h cache)
Obsidian, Galera to advance cell therapy following reverse merger
2026-04-15 09:13 · Yahoo
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
2026-04-14 18:08 · Yahoo
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
2026-04-14 12:54 · Yahoo
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary
2026-04-08 12:00 · Yahoo
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
2025-10-22 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.